Get regular updates to your inbox.
A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics…
The U.S. Food and Drug Administration has approved Neuronascent’s investigational new drug (IND) application for NNI-362, its therapy candidate for Alzheimer’s disease, allowing it to move ahead with a Phase 1a clinical trial, the company announced. The first-in-human trial will evaluate the safety of NNI-362 in…
Acadia Pharmaceuticals is starting its Phase 3 HARMONY trial to evaluate Nuplazid (pimavanserin) as a treatment for hallucinations and delusions associated with dementia-related psychosis. Currently, there is no approved therapy for this condition. Acadia’s announcement comes in the wake of the U.S. Food and Drug Administration designating Nuplazid a Breakthrough…
The $100 million IDEAS (Imaging Dementia — Evidence for Amyloid Scanning) Study is working closely with researchers and government officials to add three additional studies to the main project, where more than 18,000 people with cognitive deterioration but whose diagnosis is unclear are receiving a brain amyloid PET…
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit…
A new study led by biomedical scientists at Indiana University has revealed evidence that the NMNAT2 enzyme may be protective against the debilitating effects of certain degenerative disorders, including Alzheimer’s Disease. The study, “NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies,” was published in the journal…
A collaboration between researchers at two universities in Halifax, Nova Scotia, in Canada has resulted in the discovery of an innovative, non-invasive diagnostic agent for Alzheimer’s disease, where before such a definitive diagnosis would have been possible only from a brain autopsy. However, new findings by research teams led by…
It is widely accepted that exercise is good for your health, but can it even increase brain cells? That is the conclusion from several new reports published in the first issue of the journal Brain Plasticity. Overall, the publications presented several pieces of compelling evidence revealing that exercise benefits the brain,…
Amyloid plaques impair astrocyte function to regulate brain vessels’ blood flow in Alzheimer’s disease. These are the findings from a study entitled “Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer’s disease,” published in the journal Brain. In this study, the researchers investigated the role of…
As a disease that is best detected and treated early after onset, Alzheimer disease is characterized by a variety of aberrantly regulated proteins and molecules, which once identified can be used as biomarkers for disease and integrated into Alzheimer’s diagnostic tests. New research at the University of Illinois at Chicago by co-authors Dr.
Get regular updates to your inbox.